Lenalidomide

Lenalidomide is a thalidomide analogue indicated for the treatment of patients with:

• Multiple myeloma (MM), in combination with dexamethasone 
• MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) 
• Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities
• Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib

Limitations of Use: Lenalidomide is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials